Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Rises By 44.9%

Tharimmune, Inc. (NASDAQ:THAR) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 20,000 shares, an increase of 44.9% from the August 15th total of 13,800 shares. Based on an average daily trading volume, of 48,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.8% of the shares of the company are short sold.

Tharimmune Stock Performance

Shares of NASDAQ THAR traded down $0.09 during midday trading on Monday, reaching $2.88. 216,205 shares of the company were exchanged, compared to its average volume of 38,429. The stock has a fifty day simple moving average of $3.15 and a 200 day simple moving average of $4.47. Tharimmune has a 1 year low of $2.54 and a 1 year high of $142.50.

Tharimmune (NASDAQ:THAR) last issued its quarterly earnings results on Friday, August 9th. The company reported ($2.42) earnings per share for the quarter.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).